ClinicalTrials.gg
CompletedNCT05730023MAINSTREAMUpdated Nov 20, 2026

A Multimodal Approach for Clinical Diagnosis and Treatment of Primary Progressive Aphasia, MAINSTREAM ID:3430931

An interventional study of Active tDCS and individualized language training in Primary Progressive Aphasia, sponsored by IRCCS Centro San Giovanni di Dio Fatebenefratelli. Completed at 4 sites in Italy. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by IRCCS Centro San Giovanni di Dio Fatebenefratelli · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Now CompletedStudy completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

Primary Progressive Aphasia (PPA) is a syndrome due to different neurodegenerative disorders selectively disrupting language functions. PPA specialist care is underdeveloped. There are very few specialists (neurologists, psychiatrists, neuropsychologists and speech therapists) and few hospitals- or community-based services dedicated to diagnosis and continuing care. Currently, healthcare systems struggle to provide adequate coverage of diagnostic services, and care is too often fragmented, uncoordinated, and unresponsive to the needs of people with PPA and their families. Recently attention has been gained by digital-health technologies, such immunoassay analyzer and high-field MRI, the most promising approaches to increase our understanding of neurodegeneration, and by new non-invasive brain stimulation techniques such as transcranial direct current stimulation (tDCS) that allow a personalized treatment approach. Our goal is to develop a new treatment approach in PPA in which the regional secondary care centers participating in this project should be the hub of a regional network. The MAINSTREAM (WP2- Efficacy of personalized training in the early stage of PPA) looks forward to introduce and evaluate therapeutic innovation such as tDCS coupled with language therapy in rehabilitation settings (WP2 Early Treatment).

This objective will be pursued by conducting a randomized controlled pilot study in order to evaluate the efficacy of a combined treatment of Active (anodal) tDCS and individualized language training compared to Placebo tDCS combined with individualized language training in a subgroup of mild PPA defined using the Progressive Aphasia Severity Scale (PASS) (Sapolsky D, Domoto-Reilly K, Dickerson BCJA. Use of the Progressive Aphasia Severity Scale (PASS) in Monitoring Speech and Language Status in PPA. (2014) 28(8-9):993-1003).

Read the detailed description

60 patients with PPA will be recruited from IRCCS Istituto Centro San Giovanni di Dio, Fatebenefratelli, Brescia; IRCCS Fondazione Istituto Neurologico Nazionale C. Mondino, Pavia; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan and Fondazione Don Carlo Gnocchi - ONLUS, Milan.

The diagnostic evaluation will include cognitive and language testing, neurologic examination and neuroimaging (Magnetic Resonance Imaging (MRI) or Positron Emission Tomography PET)).

All the patients will undergo five consecutive days a week for two weeks of treatment sessions of 25 minutes:

  • 30 patients will receive Active tDCS over dorsolateral prefrontal cortex-DLPFC (anode over the left DLPFC with the cathode over the right supraorbital region) while performing an individualized language training;
  • 30 patients will receive Placebo tDCS during an individualized language training.

The two groups will be matched for sex, age, education, language severity (as defined in the Frontotemporal Dementia Clinical Dementia Rating subscale), and overall severity according to the FTD Clinical Dementia Rating.

Two trained neuropsychologists will administer the neuropsychological testing at baseline (T0), post-treatment (T1) and 3-months (T2) follow-up. All of assessments will be conducted by the same assessor.

To elucidate the mechanisms underlying tDCS effects, Magnetic Resonance Imaging (MRI) and bimolecular data will be collected at T0 and T1 (after the treatment).

02

Conditions studied

  • Primary Progressive Aphasia

Keywords

  • Behavioral and neural effects of tDCS combined with language training
  • Alzheimer's disease and other dementias
03

In context

Aphasia, Primary Progressive

77 studies on the registry are indexed under Aphasia, Primary Progressive; 28 are open to participants now.

This study's enrollment of 70 is above the median of 30 across 60 interventional studies indexed under Aphasia, Primary Progressive.

Browse Aphasia, Primary Progressive studies →

Lead sponsor

IRCCS Centro San Giovanni di Dio Fatebenefratelli is the lead sponsor of 36 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis PPA according to the current clinical criteria (Gorno-Tempini et al., 2011);
  • Mild PPA defined using the Progressive Aphasia Severity Scale (PASS);
  • Italian native speakers.

Exclusion criteria

Exclusion Criteria:

  • Presence of developmental disorders;
  • Presence of any medical or psychiatric illness that could interfere in completing assessments;
  • Presence of any medical condition that represents a to tDCS.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Active tDCS plus individualized language training

    The group will receive five consecutive days a week for two weeks of 25 minutes sessions of Active tDCS combined with an individualized language training

    Device: Active tDCS · Behavioral: individualized language training

  • Active comparator
    Placebo tDCS plus individualized language training

    The group will receive five consecutive days a week for two weeks of 25 minutes sessions of Placebo tDCS combined with an individualized language training

    Behavioral: individualized language training · Device: Placebo tDCS

Interventions

  • DeviceActive tDCS

    Active tDCS (anode will be applied over the left DLPFC with the cathode over the right supraorbital region);

  • Behavioralindividualized language training

    individualized language training

  • DevicePlacebo tDCS

    Placebo tDCS (the current will be turned off 10 seconds after the beginning and turned on for the last 10 seconds of the stimulation period);

06

What researchers measure

Primary outcomes

  1. Change in measure of naming as assessed by International Picture Naming Project Task (IPNP)

    International Picture Naming Project Task (IPNP): trained (score range: min= 0, max= 32, higher score=better outcome) and untrained object items (score range: min= 0, max= 32, higher score=better outcome); action items (score range: min= 0, max= 60, higher score=better outcome).

    Time frame: Baseline up to 2 weeks and 3 months

Secondary outcomes

  1. Change in measure of quality of life as assessed by Stroke and Aphasia Quality of Life Scale - 39 (SAQoL-39)

    Stroke and Aphasia Quality of Life Scale - 39 (SAQoL-39) is a measure of health-related quality of life in people with long-term aphasia. It provides a total score from 1 to 5 (higher score=better outcome) and it analyzes the following four domains: physical (score range: min= 1, max= 5, higher score=better outcome); psychosocial (score range: min= 1, max= 5, higher score=better outcome); communication (score range: min= 1, max= 5, higher score=better outcome) and energy (score range: min= 1, max= 5, higher score=better outcome).

    Time frame: Baseline up to 2 weeks and 3 months

  2. Change in measure of quality of life as assessed by Communication Outcome After Stroke (COAST)

    Communication Outcome After Stroke (COAST) is a measure of the functional communication in daily activities and of the impact of the quality of life point of view of aphasia patient (COAST total score range: min= 0, max= 80, higher score=better outcome) and their carer (Carer COAST total score range: min= 0, max= 80, higher score=better outcome).

    Time frame: Baseline up to 2 weeks and 3 months

  3. Change in measure of quality of life as assessed by Functional Outcome Questionnaire-aphasia

    Functional Outcome Questionnaire-aphasia is a measure of aphasia's functional and pragmatic communication in home and community settings, It provides a total score from 32 to 160 (higher score=better outcome) and it is divided into four subscales: communicating basic needs (CBN score range: min= 1, max= 35, higher score=better outcome); making routine requests (MRR score range: min= 1, max= 35, higher score=better outcome); communicating new information (CNI score range: min= 1, max= 40, higher score=better outcome) and attention/other communication skills (AO score range: min= 1, max= 50, higher score=better outcome).

    Time frame: Baseline up to 2 weeks and 3 months

  4. Change in dementia severity as assessed by Frontotemporal Dementia- Clinical Dementia Rating Scale (FTD-CDR)- Sum of Boxes

    Frontotemporal Dementia- Clinical Dementia Rating Scale (FTD-CDR)- Sum of Boxes (score range: min= 0, max= 24, higher score=worse outcome).

    Time frame: Baseline up to 2 weeks and 3 months

  5. Change in dementia severity as assessed by Global Clinical Dementia Rating (CDR) plus NACC FTLD

    Global Clinical Dementia Rating (CDR) plus NACC FTLD (score range: min= 0, max= 3, higher score=worse outcome).

    Time frame: Baseline up to 2 weeks and 3 months

  6. Change in aphasia severity as assessed by Progressive Aphasia Severity Scale (PASS)

    PASS is a measure of severity and progression of language deficits in patients with PPA. The scale assesses ten linguistic domains (each score range: min= 0, max= 3): articulation (higher score=worse outcome), fluency (higher score=worse outcome), syntax and grammar (higher score=worse outcome), word retrieval and expression (higher score=worse outcome), repetition (higher score=worse outcome), auditory comprehension (higher score=worse outcome), single word comprehension (higher score=worse outcome), reading (higher score=worse outcome), writing (higher score=worse outcome) and functional communication (higher score=worse outcome). Moreover, it analyzes three supplemental domains (each score range: min= 0, max= 3): initiation of conversation (higher score=worse outcome), turn taking during conversation (higher score=worse outcome) and generation of language (higher score=worse outcome).

    Time frame: Baseline up to 2 weeks and 3 months

  7. Change in functional communication skills as assessed by Lincoln Speech Questionnaire

    Lincoln Speech Questionnaire provides a speech score (score range: min= 0, max= 14, higher score=better outcome) and an understanding score (score range: min= 0, max= 5, higher score=better outcome).

    Time frame: Baseline up to 2 weeks and 3 months

  8. Change in aphasia severity as assessed by Communication Severity Rating Scale (Goodglass and Kaplan)

    Communication Severity Rating Scale (Goodglass and Kaplan): score range: min= 0, max= 5, higher score=better outcome.

    Time frame: Baseline up to 2 weeks and 3 months

  9. Change in depressive symptoms as assessed by Beck Depression Inventory (BDI)

    Beck Depression Inventory (BDI): score range: min= 0, max= 63, higher score=worse outcome

    Time frame: Baseline up to 2 weeks and 3 months

  10. Change in behavior and personality as assessed by Frontal Behavioral Inventory (FBI)

    Frontal Behavioral Inventory (FBI): score range: min= 0, max= 72, higher score=worse outcome.

    Time frame: Baseline up to 2 weeks and 3 months

  11. Change in measure of naming as assessed by Picture Naming subtest from Screening for Aphasia in NeuroDegeneration (SAND)

    Picture Naming subtest from Screening for Aphasia in NeuroDegeneration (SAND) provides total score (score range: min= 0, max= 14, higher score=better outcome), living score (score range: min= 0, max= 7, higher score=better outcome) and non-living score (score range: min= 0, max= 7, higher score=better outcome).

    Time frame: Baseline up to 2 weeks and 3 months

  12. Change in measure of comprehension as assessed by Auditory sentence comprehension subtest from Screening for Aphasia in NeuroDegeneration (SAND)

    Auditory sentence comprehension subtest from Screening for Aphasia in NeuroDegeneration (SAND): total score range: min= 0, max= 8, higher score=better outcome.

    Time frame: Baseline up to 2 weeks and 3 months

  13. Change in measure of comprehension as assessed by Single-word comprehension subtest from Screening for Aphasia in NeuroDegeneration (SAND)

    Single-word comprehension subtest from Screening for Aphasia in NeuroDegeneration (SAND) provides total score (score range: min= 0, max= 12, higher score=better outcome), living score (score range: min= 0, max= 6, higher score=better outcome) and non-living score (score range: min= 0, max= 6, higher score=better outcome).

    Time frame: Baseline up to 2 weeks and 3 months

  14. Change in measure of repetition as assessed by Repetition subtest from Screening for Aphasia in NeuroDegeneration (SAND)

    Repetition subtest from Screening for Aphasia in NeuroDegeneration (SAND) provides total score (score range: min= 0, max= 10, higher score=better outcome), words score (score range: min= 0, max= 6, higher score=better outcome) and non-words score (score range: min= 0, max= 4, higher score=better outcome).

    Time frame: Baseline up to 2 weeks and 3 months

  15. Change in measure of repetition as assessed by Sentence repetition subtest from Screening for Aphasia in NeuroDegeneration (SAND)

    Sentence repetition subtest from Screening for Aphasia in NeuroDegeneration (SAND) provides total score (score range: min= 0, max= 6, higher score=better outcome), predictable sentences score (score range: min= 0, max= 3, higher score=better outcome) and unpredictable sentences score (score range: min= 0, max= 3, higher score=better outcome).

    Time frame: Baseline up to 2 weeks and 3 months

  16. Change in measure of reading as assessed by Reading subtest from Screening for Aphasia in NeuroDegeneration (SAND)

    Reading subtest from Screening for Aphasia in NeuroDegeneration (SAND) provides total score (score range: min= 0, max= 16, higher score=better outcome), words score (score range: min= 0, max= 12, higher score=better outcome) and non-words score (score range: min= 0, max= 4, higher score=better outcome).

    Time frame: Baseline up to 2 weeks and 3 months

  17. Change in measure of writing as assessed by Writing subtest from Screening for Aphasia in NeuroDegeneration (SAND)

    Writing subtest from Screening for Aphasia in NeuroDegeneration (SAND) provides Information Units score (score range: min= 0, max= 6, higher score=better outcome), total number of words score (score range: min= 0, max= no limits, higher score=better outcome), number of nouns/total number of words score (score range: min= 0, max= 1, higher score=better outcome), number of verbs/total number of words (score range: min= 0, max= 1, higher score=better outcome), number of correct syntactic structures/total number of syntactic structures score (score range: min= 0, max= 1, higher score=better outcome), number of orthographic errors score (score range: min= 0, max= no limits, higher score=worse outcome), number of lexico-semantic errors/number of words score (score range: min= 0, max= 1, higher score=worse outcome).

    Time frame: Baseline up to 2 weeks and 3 months

  18. Change in measure of semantics as assessed by Semantic association subtest from Screening for Aphasia in NeuroDegeneration (SAND)

    Semantic association subtest from Screening for Aphasia in NeuroDegeneration (SAND): total score range: min= 0, max= 4, higher score=better outcome.

    Time frame: Baseline up to 2 weeks and 3 months

  19. Change in measure of oral production as assessed by Picture description subtest from Screening for Aphasia in NeuroDegeneration (SAND)

    Picture description subtest from SAND provides Information Units score (score range: min= 0, max= 8, higher score=better outcome), total number of words score (score range: min= 0, max= no limits, higher score=better outcome), number of nouns/total number of words score (score range: min= 0, max= 1, higher score=better outcome), number of verbs/total number of words score (score range: min= 0, max= 1, higher score=better outcome), number of sentences score (score range: min= 0, max= no limits, higher score=better outcome), number of subordinates/number of sentences score (score range: min= 0, max= no limits, higher score=better outcome), number of repaired sequences/number of words score (score range: min= 0, max= 1, higher score=worse outcome), number of phonological errors/number of words (score range: min= 0, max= 1, higher score=worse outcome), number of lexico-semantic errors/number of words (score range: min= 0, max= 1, higher score=worse outcome).

    Time frame: Baseline up to 2 weeks and 3 months

  20. Change in measure of naming as assessed by Subtest from Aachener Aphasie Test (AAT)

    Naming subtest from Aachener Aphasie Test (AAT): score range: min= 0, max= 120, higher score=better outcome.

    Time frame: Baseline up to 2 weeks and 3 months

  21. Change in measure of object naming as assessed by Subtest from Battery for the Assessment of Aphasic Disorders (BADA)

    Subtest from Battery for the Assessment of Aphasic Disorders (BADA): score range: min= 0, max= 30, higher score=better outcome.

    Time frame: Baseline up to 2 weeks and 3 months

  22. Change in measure of fluency abilities as assessed by Verbal Fluency (semantic and phonemic)

    Verbal Fluency (semantic and phonemic): score range min= 0, max= no limits, higher score=better outcome.

    Time frame: Baseline up to 2 weeks and 3 months

  23. Change in measure of constructional praxia as assessed by Rey-Osterrieth Complex Figure-Copy

    Rey-Osterrieth Complex Figure-Copy: score range min= 0, max= 36, higher score=better outcome.

    Time frame: Baseline up to 2 weeks and 3 months

  24. Change in measure of verbal long-term memory as assessed by Story Recall

    Story Recall: score range min= 0, max= 28, higher score=better outcome.

    Time frame: Baseline up to 2 weeks and 3 months

  25. Change in measure of nonverbal long-term memory as assessed by Rey-Osterrieth Complex Figure-Recall

    Rey-Osterrieth Complex Figure-Recall: score range min= 0, max= 36, higher score=better outcome.

    Time frame: Baseline up to 2 weeks and 3 months

  26. Change in measure of attentional abilities as assessed by Trial Making Test

    Trial Making Test: score range: min= n/a, max= no limits, higher score=worse outcome.

    Time frame: Baseline up to 2 weeks and 3 months

  27. Change in measure of executive abilities as assessed by Stroop Test

    Stroop Test: score range: min= n/a, max= no limits, higher score=worse outcome.

    Time frame: Baseline up to 2 weeks and 3 months

  28. Change in measure of global cognitive impairment as assessed by Mini Mental State Examination (MMSE)

    Mini Mental State Examination (MMSE): score range: min= 0, max= 30, higher score=better outcome.

    Time frame: Baseline up to 2 weeks and 3 months

  29. Change in molecular biomarkers as assessed by the size and the concentration of plasma Extracellular vesicles (EVs)

    Size and the concentration of plasma EVs

    Time frame: Baseline up to 2 weeks

  30. Change in molecular biomarkers as assessed by Neurofilament light chain (NFL) levels

    Neurofilament light chain (NFL) levels

    Time frame: Baseline up to 2 weeks

  31. Change in molecular biomarkers as assessed by Glial Fibrillary Acidic Protein (GFAP) levels

    Glial Fibrillary Acidic Protein (GFAP) levels

    Time frame: Baseline up to 2 weeks

  32. Change in molecular biomarkers as assessed by brain-derived neurotrophic factor (BDNF)

    Brain-derived neurotrophic factor (BDNF) levels

    Time frame: Baseline up to 2 weeks

  33. Change in molecular biomarkers as assessed by neurogranin levels

    Neurogranin levels

    Time frame: Baseline up to 2 weeks

  34. Change in functional connectivity as derived from resting-state functional MRI

    Functional connectivity as derived from resting-state functional MRI

    Time frame: Baseline up to 2 weeks

  35. Change in structural connectivity as derived from diffusion-weighted MRI

    Structural connectivity as derived from diffusion-weighted MRI

    Time frame: Baseline up to 2 weeks

07

Study locations

4 sites
  • Maria Cotelli
    Brescia, BS 25125, Italy
  • Stefano F. Cappa
    Pavia, PV 27100, Italy
  • Francesca Baglio
    Milan, 20148, Italy
  • Tiziana Carandini
    Milan, 20122, Italy
08

References and documents

Publications

  • Cotelli M, Baglio F, Manenti R, Blasi V, Galimberti D, Gobbi E, Pagnoni I, Rossetto F, Rotondo E, Esposito V, De Icco R, Giudice C, Tassorelli C, Catricala E, Perini G, Alaimo C, Campana E, Benussi L, Ghidoni R, Binetti G, Carandini T, Cappa SF. A Multimodal Approach for Clinical Diagnosis and Treatment of Primary Progressive Aphasia (MAINSTREAM): A Study Protocol. Brain Sci. 2023 Jul 12;13(7):1060. doi: 10.3390/brainsci13071060. PubMed 37508992 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Jan 2026, 35 months.

Of 38 non-industry interventional studies with no phase under Aphasia, Primary Progressive, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 59. This study's 35 months is below that.

Counting every sponsor, half of 38 studies reached it within 40 months; a quarter within 26 and three quarters within 59.

Completion moved once since we started tracking on Sep 25, 2026: Feb 2026 → Jan 2026, on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2023
First posted
Feb 15, 2023
StartActual
Feb 1, 2023
Primary completionActual
Jan 13, 2026
CompletionActual
Jan 13, 2026was Feb 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 20, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 Italy)
  • Francesca Baglio · Milan, Italy
  • Tiziana Carandini · Milan, Italy
Show 2 removed
  • Tiziana Carandini · Milan, Italy
  • Francesca Baglio · Milan, Italy
Nov 20, 2026
Study completion
Feb 2026→Jan 13, 2026 (actual)
Nov 20, 2026
Enrollment
60 (estimated)→70 (actual)
Nov 20, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 37508992 ↗
Nov 20, 2026
Sponsor
Collaborators added: Fondazione Regionale per la Ricerca Biomedica·IRCCS National Neurological Institute "C. Mondino" Foundation·Fondazione Don Carlo Gnocchi ETS; collaborators removed: Fondazione Regionale per la Ricerca Biomedica (FRRB)·IRCCS Fondazione Istituto Neurologico Nazionale Casimiro Mondino, Pavia·IRCCS Fondazione Don Carlo Gnocchi - ONLUS, Milan
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 37508992 ↗
    2 sites added, 2 sites removed
    Show 2 added (2 Italy)
    • Francesca Baglio · Milan, Italy
    • Tiziana Carandini · Milan, Italy
    Show 2 removed
    • Tiziana Carandini · Milan, Italy
    • Francesca Baglio · Milan, Italy
    Study completion Feb 2026→Jan 13, 2026 (now actual)
    Enrollment 60 (estimated)→70 (actual)
    Sponsor Collaborators added: Fondazione Regionale per la Ricerca Biomedica·IRCCS National Neurological Institute "C. Mondino" Foundation·Fondazione Don Carlo Gnocchi ETS; collaborators removed: Fondazione Regionale per la Ricerca Biomedica (FRRB)·IRCCS Fondazione Istituto Neurologico Nazionale Casimiro Mondino, Pavia·IRCCS Fondazione Don Carlo Gnocchi - ONLUS, Milan
    + 4 other changes: verification date, oversight details, contact details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05730023
Lead sponsor
IRCCS Centro San Giovanni di Dio Fatebenefratelli
Collaborators
Fondazione Regionale per la Ricerca Biomedica, IRCCS National Neurological Institute "C. Mondino" Foundation, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Fondazione Don Carlo Gnocchi ETS
Responsible party
Sponsor
First posted
Feb 15, 2023
Start date
Feb 1, 2023
Primary completion
Jan 13, 2026
Completion
Jan 13, 2026
Last update
Nov 20, 2026

Study contacts

Maria Cotelli
principal investigator · IRCCS Istituto Centro San Giovanni di Dio- Fatebenefratelli

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion